Incyte acquires global rights to MorphoSys’ tafasitamab

Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.

Feb 6, 2024 - 18:00

Incyte acquires global rights to MorphoSys’ tafasitamab

Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.

Read the original article

Tags:

Previous Article

Silence announces $120m private placement for depositary shares

Risk adjusted net present value: What is the current valuation of Caribou Biosci...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Datopotamab deruxtecan by Daiichi Sankyo for Head And N...

Apr 23, 2024

AMA asks doctors to de-emphasize use of BMI in gauging health and obesity

AMA asks doctors to de-emphasize use of BMI in gauging ...

Jun 14, 2023

Opinion: Doctors in the U.S. can learn a lot about advocacy and activism from their Israeli counterparts

Opinion: Doctors in the U.S. can learn a lot about advo...

Sep 12, 2023